- Somebody, somewhere sure is selling shares of Amarin (AMRN -7.1%) following a U.S. district court's ruling on generic Lovaza, but it sure is difficult to discern any negativity in the market chatter.
- Leerink's Joseph Schwartz says generic Lovaza might not compete with Vascepa on price as much as on efficacy and safety.
- There's also talk that Citi and Jefferies are out defending the shares, with Citi calling a buying opportunity.
- Additionally, there are even some notable bears that seem to think the sell-off is overdone.
From other sites
at Zacks.com (Apr 9, 2015)
at Zacks.com (Feb 25, 2015)
at Zacks.com (Feb 23, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs